{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Smoldering+Plasma+Cell+Myeloma&page=4",
    "query": {
      "condition": "Smoldering Plasma Cell Myeloma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 83,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Smoldering+Plasma+Cell+Myeloma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Smoldering+Plasma+Cell+Myeloma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T19:47:26.077Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04850846",
      "title": "Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Monoclonal Gammopathy of Undetermined Significance",
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-04-27",
      "completion_date": "2027-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Brighton",
          "state": "Massachusetts"
        },
        {
          "city": "Methuen",
          "state": "Massachusetts"
        },
        {
          "city": "Milford",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04850846"
    },
    {
      "nct_id": "NCT06365060",
      "title": "Screening for AL Amyloidosis in Smoldering Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2024-05-01",
      "completion_date": "2029-02-27",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06365060"
    },
    {
      "nct_id": "NCT02603887",
      "title": "Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Smoldering Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-07-20",
      "completion_date": "2027-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603887"
    },
    {
      "nct_id": "NCT03937635",
      "title": "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoldering Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2019-09-16",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 742,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03937635"
    },
    {
      "nct_id": "NCT03952832",
      "title": "Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoldering Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-11",
      "completion_date": "2021-06-11",
      "has_results": false,
      "last_update_posted_date": "2019-11-14",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03952832"
    },
    {
      "nct_id": "NCT05469893",
      "title": "Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-risk Smoldering Multiple Myeloma",
        "Smoldering Multiple Myeloma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Teclistamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Irene Ghobrial, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-08-10",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05469893"
    },
    {
      "nct_id": "NCT02960555",
      "title": "Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoldering Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Isatuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2017-02-08",
      "completion_date": "2030-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 3,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960555"
    },
    {
      "nct_id": "NCT01096810",
      "title": "Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "TBL 12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jagannath, Sundar, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-07-22",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01096810"
    },
    {
      "nct_id": "NCT00112827",
      "title": "Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Smoldering Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "total marrow irradiation",
          "type": "RADIATION"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "cytogenetic analysis",
          "type": "GENETIC"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "autologous-autologous tandem hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "GENETIC"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 54,
      "start_date": "2004-11",
      "completion_date": "2019-02-15",
      "has_results": true,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00112827"
    },
    {
      "nct_id": "NCT04775550",
      "title": "DARA RVD For High Risk SMM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-risk Smoldering Multiple Myeloma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omar Nadeem, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2021-03-08",
      "completion_date": "2030-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-08T19:47:26.077Z",
      "location_count": 6,
      "location_summary": "Stamford, Connecticut • Boston, Massachusetts • Foxborough, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Foxborough",
          "state": "Massachusetts"
        },
        {
          "city": "Methuen",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04775550"
    }
  ]
}